Cargando…
13. Uncommon rash and neurological symptoms related to Shingrix
BACKGROUND: Shingrix is a non-live recombinant vaccine approved by the Food and Drug Administration (FDA) in 2017 to prevent shingles and postherpetic neuralgia in immunocompetent adults age 50 years and older. A myriads of local and systemic reactions due to the vaccine have been reported, but diff...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776023/ http://dx.doi.org/10.1093/ofid/ofaa439.058 |